Despite the immense economic challenges presented by the COVID-19 pandemic, investors remain bullish on the potential of cell and gene therapies – and the sector as a whole is on track for a record-breaking year. Regenerative medicine and advanced therapy developers have raised $10.7B in financing in the first half of 2020, a 120% increase from the first half of 2019. The public market for cell and gene therapies has been particularly strong. In the first year, five companies went public – including three in the second quarter, in spite of COVID-19 – raising more than $1.4B, with an additional $4B raised in follow-on offerings. In general, the market has been extremely strong, with life sciences stock indices such as the Nasdaq Biotech Index already having made up for any losses incurred during the first weeks of the pandemic.
As the sector continues to grow, ARM brings together members and investors at our events and conferences, providing networking and presentation opportunities, as well as the ability to collaborate via partnering systems.
In addition, ARM’s Quarterly and Sector reports offer investors and members in-depth insight into the current financial and clinical landscape for regenerative medicine. Unique in scope, these reports serve as the preeminent source of information on the global regenerative medicine sector.
ARM Convenes Key Stakeholders
ARM’s events bring together industry leaders, investors, policy makers, clinicians and patients to network, partner and learn about the latest clinical and commercial successes and challenges facing the sector.
UPCOMING: OCTOBER 14-16, 2020
The 2020 Meeting on the Mesa Goes Virtual
ARM’s 2020 Meeting on the Mesa includes a virtual form of the meeting’s signature partnering system, expected to facilitate more than 3,000 one-to-one meetings between industry leaders, as well as 20+ panels and workshops and 120+ presentations from leading public and private companies in the sector. Don’t miss out on the opportunity to share the latest on your company’s platform technology, preclinical advances, and clinical data at the preeminent conference for the cell therapy, gene therapy, and broader regenerative medicine field.
The first ARM Connect, an event centered around virtual networking, available exclusively and free of charge to ARM members, took place in July and facilitated more than 750 conversations between attendees. Sign up for ARM’s mailing list and receive notifications for future ARM Connect events!
Sign Up for Our Newsletter & Receive Updates on ARM’s Slate of Events
In addition to compiling the latest business, clinical, and policy news in the regenerative medicine sector, ARM’s newsletter includes up-to-the-minute updates on opportunities to attend and present at ARM’s slate of cell and gene therapy-focused events. Make sure your company isn’t missing out – sign up to receive news and updates from ARM today!
What Biotechs Need to Know About Fundraising During COVID-19
View the webinar playback featuring Gbola Amusa of Chardan, John Maslowski of Castle Creek Biosciences and Jason Pitts of Sofinnova Investments as they discuss the immense economic challenges brought on by COVID-19 and the impact on investment in the cell and gene therapy space. Topics include the current funding landscape, what investors are looking for when evaluating new and follow-on opportunities, and how companies can best prepare to fundraise during the pandemic.